BXRX | Baudax Bio, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.1864 - 0.1864
52 Week Range	0.1864 - 0.1864
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	N/A
Average Volume	N/A
Shares Outstanding	43,593,100
Market Cap	8,125,754
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-11-14

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	-94.13
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	9
Country	USA
Website	BXRX

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

BXRX's peers: DRMA, HOTH, SNGX, TENX, UBX, CMND

*Chart delayed

Analyzing fundamentals for BXRX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is on medium level and Health is frighteningly weak. For more detailed analysis please see BXRX Fundamentals page.

Watching at BXRX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on BXRX Technicals page.